BSX vs. CYTK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BSX and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BSX | CYTK |
|---|---|---|
| Company Name | Boston Scientific Corporation | Cytokinetics, Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 156.69 billion USD | 4.23 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | May 19, 1992 | April 30, 2004 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BSX and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BSX | CYTK |
|---|---|---|
| 5-Day Price Return | 0.37% | -4.54% |
| 13-Week Price Return | 0.96% | 12.80% |
| 26-Week Price Return | 4.75% | -24.27% |
| 52-Week Price Return | 32.67% | -36.38% |
| Month-to-Date Return | 0.55% | -6.14% |
| Year-to-Date Return | 18.11% | -24.89% |
| 10-Day Avg. Volume | 5.90M | 1.77M |
| 3-Month Avg. Volume | 7.12M | 1.68M |
| 3-Month Volatility | 18.37% | 42.22% |
| Beta | 0.64 | 0.55 |
Profitability
Return on Equity (TTM)
BSX
11.51%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
BSX’s Return on Equity of 11.51% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
CYTK
-132.03%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
CYTK has a negative Return on Equity of -132.03%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
BSX
13.55%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
A Net Profit Margin of 13.55% places BSX in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
CYTK
-707.17%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
CYTK has a negative Net Profit Margin of -707.17%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
BSX
17.02%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
BSX’s Operating Profit Margin of 17.02% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
CYTK
-637.96%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
CYTK has a negative Operating Profit Margin of -637.96%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | BSX | CYTK |
|---|---|---|
| Return on Equity (TTM) | 11.51% | -132.03% |
| Return on Assets (TTM) | 6.30% | -45.52% |
| Net Profit Margin (TTM) | 13.55% | -707.17% |
| Operating Profit Margin (TTM) | 17.02% | -637.96% |
| Gross Profit Margin (TTM) | 68.30% | -- |
Financial Strength
Current Ratio (MRQ)
BSX
1.37
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
BSX’s Current Ratio of 1.37 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CYTK
6.76
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
CYTK’s Current Ratio of 6.76 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BSX
0.52
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
BSX’s Debt-to-Equity Ratio of 0.52 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CYTK
6.03
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.03, CYTK operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
BSX
8.48
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
BSX’s Interest Coverage Ratio of 8.48 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
CYTK
-16.50
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
CYTK has a negative Interest Coverage Ratio of -16.50. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | BSX | CYTK |
|---|---|---|
| Current Ratio (MRQ) | 1.37 | 6.76 |
| Quick Ratio (MRQ) | 0.76 | 6.61 |
| Debt-to-Equity Ratio (MRQ) | 0.52 | 6.03 |
| Interest Coverage Ratio (TTM) | 8.48 | -16.50 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BSX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
BSX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BSX
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
BSX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BSX | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BSX
62.29
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
A P/E Ratio of 62.29 places BSX in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
CYTK
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for CYTK is currently unavailable.
Price-to-Sales Ratio (TTM)
BSX
8.44
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
BSX’s P/S Ratio of 8.44 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
CYTK
52.60
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
CYTK’s P/S Ratio of 52.60 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
BSX
7.09
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
BSX’s P/B Ratio of 7.09 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
CYTK
58.48
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 58.48, CYTK’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | BSX | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 62.29 | -- |
| Price-to-Sales Ratio (TTM) | 8.44 | 52.60 |
| Price-to-Book Ratio (MRQ) | 7.09 | 58.48 |
| Price-to-Free Cash Flow Ratio (TTM) | 44.81 | 78.61 |